`
`____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________
`
`KVK-Tech, Inc.
`Petitioner
`
`v.
`
`Shire PLC
`Patent Owner
`
`____________________
`
`Case IPR2017-00290
`U.S. Patent No. 8,846,100
`
`____________________
`
`DECLARATION OF THOMAS HEDEMANN IN SUPPORT OF MOTION
`FOR ADMISSION PRO HAC VICE
`
`KVK-TECH EXHIBIT 1042
`
`
`
`I, Thomas Hedemann, declare as follows:
`
`1.
`
`I was admitted to the Connecticut Bar in 2005. I have been practicing
`
`law for over 12 years. For more than 10 years my practice has focused primarily
`
`on patent litigation.
`
`2.
`
`Over the course of my career, I have been counsel in over 10 patent
`
`litigations.
`
`3.
`
`I am a member of good standing in the Connecticut Bar and am
`
`admitted to practice before the U.S. District Court of Connecticut. I am also
`
`admitted to practice before the U.S. Court of Appeals for the Federal Circuit and
`
`the U.S. Supreme Court.
`
`4.
`
`5.
`
`My Connecticut Bar membership number is 424936.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`6.
`
`I have never had a court or administrative body deny my application
`
`for admission to practice.
`
`7.
`
`I have read and will comply with the Patent Office Trial Practice
`
`Guide and the Board’s Rules for Practice for Trials, as set forth in 37 C.F.R. Part
`
`42.
`
`
`
`8.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`9.
`
`I have currently applied to appear pro hac vice in the following related
`
`proceeding before the United States Patent and Trademark Office IPR2017-00293.
`
`I have not applied to appear pro hac vice before the United States Patent and
`
`Trademark Office in any other proceedings in the last three years.
`
`10.
`
`I am intimately familiar with the subject matter of U.S. Patent No.
`
`8,846,100. I am also intimately familiar with amphetamine salt formulations, such
`
`as Adderall XR® as a result of my participation as counsel in litigation related to
`
`Adderall XR®, specifically, Shire LLC et al. v. Abhai, LLC, 1:15-cv-13909 (D.
`
`Mass.). In addition, I have represented a number of life sciences and
`
`pharmaceutical companies in patent litigation matters before federal district
`
`courts and appellate courts. The technology in these disputes includes
`
`pharmaceutical compounds, including those for the treatment of attention deficit
`
`disorder, and method-of-treatment claims.
`
`11.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true; and further that these statements and the like are punishable by
`
`
`
`fine, imprisonment, or both under Section 1001 of Title 18 of the United States
`
`Code.
`
`Date: January 9, 2018
`
` Respectfully submitted,
`
`/s/ Thomas Hedemann
`Thomas Hedemann
`Axinn, Veltrop & Harkrider LLP
`90 State House Square Hartford,
`CT 06103
`(860) 275-8100
`
`